CSL shares up 17% as immunoglobulin boost points to signs of recovery

After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL has flashed signs of recovery, projecting mid-single-digit growth in fiscal year 2027 for its largest sector, CSL Behring.